What do systematic reviews say?

Platinum‐containing chemotherapy vs chemotherapy without platinum

The review found no eligible studies for this question.

• Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

OFS vs no OFS

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 2996 participants
  Low

Taxane‐containing chemotherapy vs any chemotherapy without taxane

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 7 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Non‐intensive vs intensive follow‐up

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 639 participants
  High

Summary of findings: Decentralised vs centralised follow‐up

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 356 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Moderate

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Exercise vs usual care

• Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 123 participants
  Very low

Exercise vs usual care

• Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 136 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Very low